Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Insights - The stock reaction following the conference call was considered unusual, with no new information presented beyond what was preannounced at JPMorgan [1] - The company highlighted robust new patient starts, which increased significantly, showing a 6x growth compared to the BMS launch, rising from 204 in Q3 to 216 in Q4 [1] Market Reaction - The market has experienced significant volatility this week, impacting stock performance [1] - The company aimed to provide additional context regarding the preannounced results during the conference call [1] Patient Metrics - New patient starts have been strong, indicating positive growth trends for the company [1] - The increase in new patient starts raises questions about the perceived gap between these starts and other performance metrics [1]